menu
    • menu
    [{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"AB001","moa":"ACE2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"AB001","moa":"ACE2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"AB001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTBIO \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ARTBIO \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for AB001

    Menu

    AB001

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ARTBIO

                            Norway arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            ARTBIO

                            Norway arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001

                            Details : AB001 is a novel PSMA-targeted and Pb212-based radioligand therapy designed to treat patients with metastatic prostate cancer.

                            Product Name : AB001

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 09, 2025

                            Lead Product(s) : AB001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Frontier Biotechnologies

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Frontier Biotechnologies

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects

                            Details : AB001 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Back Pain.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 25, 2019

                            Lead Product(s) : AB001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Frontier Biotechnologies

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Frontier Biotechnologies

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

                            Details : AB001 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Back Pain.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 07, 2015

                            Lead Product(s) : AB001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth